Deforming dorsopathy in patients with the combination of arterial hypertension, dyslipidemia, obesity: possible solutions of the problem

Resume. Deforming dorsopathy diagnosed in more than 45 % of the population in developed countries is a widespread specie of the musculoskeletal system pathology. In this regard, the adequate therapy for combinations of these pathological conditions is relevant. Material and methods. The study involved 73 patients aged over 55 years with spinal osteochondrosis in the acute stage in combination with metabolic syndrome, which were at random divided into two groups: 46 people formed the core group (group 1) and 27 - the comparison group (group 2). To patients of the main group with the purpose of treatment of vertebrogenic dorsopatia, edema and dorsalgia, a complex enzyme medicine (composition: bromelain 450 FIP, trypsin 1440 FIP, rutoside 100 mg), 2 tablets 3 times a day per os for 30-40 minutes before meals was prescribed. Simultaneously appointed generally accepted (standard) treatment (health-protective mode, diet, physiotherapy, chondroprotectors, muscle relaxants, nonsteroidal anti-inflammatory drugs (diclofenac sodium), while the comparison group was only standard treatment of dorsopatia. Evaluation of pain and asthenia was conducted once before start of treatment and every day during treatment. Before treatment and after 12 days of it the study was conducted, which included an assessment of the clinical analysis of blood, blood's lipids level, glucose's level, a condition of hemostasis system, the concentration levels of acute phase proteins. Conclusion. It has been revealed that the application of enzymes in the treatment of comorbid conditions: dorsopathia, combined with hypertension and dyslipidemia and impaired glucose metabolism makes possible not only to reduce manifestations of inflammation, but to reduce the risk of thrombosis and accordingly reducing the risk of fatal complications of cardiovascular diseases.

1. Voropai N.G, Doronina О.B. Application of systemic enzymotherapy in dorsopathies in patients with undifferentiated connective tissue dysplasia // Bulletin of Siberian medicine, 2008. Annex 1. p. 196-199. (in Russian)
2. Zborowski A. B., Stadjarov M. Yu., Brain E. E. Systemic enzyme in the treatment of rheumatic diseases // J. Scientific and practical rheumatology №1, 2003. p. 64-69. (in Russian)
3. Palekhov A.V., Minaev S.V. Organizational and methodological aspects of palliative care to cancer patients in Stavropol Krai // Palliative medicine and rehabilitation. 2000. №4. P.53-54. (in Russian)
4. Repina M.A., Korzo T.M., Zinina T.A., Riskevitch S.R. Correction of vascular-platelet hemostasis in peri - and postmenopausal women with drug Phlogenzym // Journal of obstetrics and gynecological diseases. 1999. Vol. 3. T. XLVIII. C. 25-29. (in Russian)
5. Systemic enzyme. Theoretical foundations, clinical experience. / Ed. by K. N. Veremeenko, V. N. Kovalenko. Kyiv. 2000. (in Russian)
6. Yakimova A.V. Influence of polyenzyme medicine "Wobenzym" on the activity of destructive inflammatory process in complex therapy of pulmonary tuberculosis/ A.V. Yakimova, Ievlev-Duntau A.P., Lipsky K.A., Trunov A.N., SHKURUPIY V.A. //J.Tuberculosis and lung disease. 2010. №6. P. 47-52. (in Russian)
7. Kleine M.W., Pabst H. Die Wirkung einer oralen Enzymtherapie auf experimentell erzeugte Hдma­tome // Forum Prakt. Allgemeinarztes. 1988. 27. 42.
8. LaMarre J., Wollenberg G., Gonias S. et al. Cytokine binding and clearance properties of proteinase-activated ?2-macroglobulin // Lab. Invest. 1991. 65. 3-14.

Dolgova N.A. - chief doctor, e-mail: novdolgova@yandex.ru
Shkurupiy V.A. - doctor of medical sciences, professor, academician of the RAMS, head of the chair of pathology, directorm, e-mail: sck@soramn.ru
Yakimova A.V. - doctor of medical sciences, associate professor of the chair of obstetrics and gynecology, e-mail: yakimova@hotmil.com
Dobrovolskaya N.P. - chief of the department